Atherosclerotic Cardiovascular Disease (ASCVD) Market Insights, Epidemiology, and Forecast - 2036 | 7MM Market to Reach USD 40 Billion as Precision Therapies Reshape Growth
Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Atherosclerotic Cardiovascular Disease - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The "Atherosclerotic Cardiovascular Disease (ASCVD)- Market Insights, Epidemiology and Market Forecast - 2036" report provides a comprehensive assessment of ASCVD epidemiology, treatment practices, market dynamics, competitive developments, and commercial opportunities across the seven major markets (7MM): the United States, Germany, Spain, Italy, France, the United Kingdom, and Japan.
The ASCVD market was valued at approximately USD 24.00 billion in 2025 and is projected to reach about USD 40.00 billion by 2036, representing a 4.8% CAGR during 2026-2036. The United States accounted for the largest market share in 2025, followed by Germany. Market growth is supported by population aging, improved post-event survival, persistent cardiometabolic risk factors, earlier intervention, and expanding use of advanced lipid-lowering therapies.
ASCVD Market and Epidemiology Highlights
ASCVD Treatment Landscape and Unmet Needs
ASCVD management combines lifestyle modification, pharmacotherapy, and interventional procedures. Statins remain the foundation of lipid-lowering treatment, supported by ezetimibe, bempedoic acid, omega-3 based therapies, antiplatelet agents, anticoagulants, and anti-inflammatory therapies. Revascularization procedures may be used for patients with established disease or severe coronary artery obstruction.
PCSK9-targeted therapies, including evolocumab, alirocumab, and inclisiran, provide additional LDL-C reduction for high-risk patients who do not achieve recommended lipid targets with conventional treatment. REPATHA currently leads the PCSK9 inhibitor market, with approximately USD 1.50 billion in United States revenue in 2025. LEQVIO and emerging oral PCSK9 therapies are expected to gain market share through 2036, particularly as inclisiran patents expire in the United States in 2034 and Europe in 2035.
Significant unmet needs remain, including incomplete LDL-C control, residual inflammatory risk, Drug-Drug interaction concerns, treatment adherence challenges, clinician-dependent adoption, comorbidity burden, and limited access to advanced therapies due to pricing and reimbursement barriers. These gaps are increasing demand for convenient, durable, and multi-pathway treatment options.
ASCVD Pipeline and Competitive Landscape
The ASCVD pipeline includes oral PCSK9 inhibitors, RNA-based therapies targeting lipoprotein(a), anti-inflammatory agents, and gene-editing approaches. These candidates may improve adherence, broaden treatment eligibility, and address residual cardiovascular risk beyond conventional lipid reduction.
Olpasiran, developed by Amgen using technology advanced by Arrowhead Pharmaceuticals, is being evaluated in Phase III trials for patients with elevated Lp (a) and established ASCVD. A Phase III primary prevention study for individuals at high risk of a first cardiovascular event was also initiated in H2 2025.
Other key companies and development programs include NewAmsterdam Pharma and Menarini Group with obicetrapib, Resverlogix with apabetalone, Ionis Pharmaceuticals and Novartis with pelacarsen, LIB Therapeutics with lerodalcibep, and AstraZeneca with laroprovstat.
Drug Uptake, Pricing, and Market Access
The report evaluates therapy adoption, probability-adjusted peak patient share, launch timing, pricing, and market access. Olpasiran is expected to achieve medium-fast uptake, with a probability-adjusted peak share of 3.5% approximately seven years after launch.
Pricing analysis indicates an estimated cost of USD 3 per tablet for once-daily ezetimibe, resulting in an annual treatment cost of approximately USD 1,104. Once-daily bempedoic acid is priced at about USD 11 per tablet, corresponding to an estimated annual cost of USD 3,991. The assessment examines how pricing, reimbursement, and analogue selection may affect adherence and long-term commercial uptake.
Report Scope and Strategic Value
The ASCVD market report provides historical and forecast analysis for 2022-2036, including epidemiology-based bottom-up forecasting, market size by therapy and geography, patient share projections, treatment algorithms, pipeline profiles, patent considerations, regulatory milestones, and competitive intelligence. It also assesses diagnosis trends, treatment accessibility, patient journeys, and clinical development opportunities across North America, Europe, and Asia-Pacific.
Primary research includes perspectives from more than 10 Key Opinion Leaders across the 7MM, with outreach to over 20 experts from institutions including Jacksonville Center for Clinical Research, University of Louisville School of Medicine, and Yale School of Medicine. These insights support analysis of prescribing patterns, treatment switching, adherence, drug adoption, accessibility, and unmet medical needs.
Qualitative analysis includes SWOT and conjoint assessment of emerging ASCVD therapies based on efficacy, safety, administration frequency, route of administration, order of entry, probability of success, and addressable patient population. The report is designed to support pharmaceutical companies, investors, healthcare organizations, and strategy teams in evaluating ASCVD market opportunities, competitive positioning, clinical development priorities, and launch planning through 2036.
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key events
4.1. Upcoming Key Catalysts
4.2. Key Conferences and Meetings
4.3. Key Transactions and Collaborations
4.4. News Flow
5. Epidemiology and Market Forecast Methodology
6. Atherosclerotic Cardiovascular Disease (ASCVD) Market Overview at a Glance
6.1. Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)
6.2. Market Share (%) Distribution of ASCVD by Therapies in 7MM, in 2025
6.3. Market Share (%) Distribution of ASCVD by Therapies in 7MM, in 2036
7. Disease Background and Overview
7.1. Introduction
7.2. Associated Diseases
7.3. Pathophysiology of Atherosclerosis
7.4. Risk Factors of ASCVD
7.5. Symptoms of ASCVD
7.6. Diagnosis
7.6.1. Risk Assessment
7.6.2. Diagnostic Guidelines
7.6.2.1. Kaiser Permanente Washington Guideline for Management of ASCVD
7.6.2.2. ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease: 2019
7.6.2.3. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
7.6.2.4. ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2021
8. Treatment of ASCVD
8.1. Treatment Algorithm
8.2. Treatment Guidelines
8.2.1. ACC/AHA Guidelines on the Primary Prevention of ASCVD: 2019
8.2.2. Major Treatment Recommendations of the 2018 AHA/ACC Multisociety Cholesterol Guideline and the 2019 ESC/EAS Guidelines for Secondary ASCVD Prevention
8.2.3. Kaiser Permanente Washington Guideline for the Management of ASCVD
8.2.4. Japan Atherosclerosis Society (JAS) Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2017
8.2.5. ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2021
9. Epidemiology and Patient Population of ASCVD
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Total Diagnosed Prevalent Cases of ASCVD in the 7MM
9.4. The United States
9.4.1. Total Diagnosed Prevalent Cases of ASCVD in the US
9.4.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in the US
9.4.3. Age-specific Diagnosed Prevalent Cases of ASCVD in the US
9.4.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in the US
9.4.5. Systemic inflammation in ASCVD in the US
9.5. EU4 and the UK
9.5.1. Total Diagnosed Prevalent Cases of ASCVD in EU4 and the UK
9.5.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in EU4 and the UK
9.5.3. Age-specific Diagnosed Prevalent Cases of ASCVD in EU4 and the UK
9.5.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in EU4 and the UK
9.5.5. Systemic inflammation in ASCVD in EU4 and the UK
9.6. Japan
9.6.1. Total Diagnosed Prevalent Cases of ASCVD in Japan
9.6.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in Japan
9.6.3. Age-specific Diagnosed Prevalent Cases of ASCVD in Japan
9.6.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in Japan
9.6.5. Systemic Inflammation in ASCVD in Japan
10. Patient Journey of ASCVD
11. Marketed Therapies
11.1. Key Cross Competition
11.2. Evolocumab (REPATHA): Amgen
11.2.1. Drug Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Summary of Pivotal Trial
11.2.5. Clinical Development
11.2.5.1. Clinical trials information
11.2.6. Analyst Views
11.3. Inclisiran (LEQVIO): Novartis/Alnylam Pharmaceuticals
11.3.1. Drug Description
11.3.2. Regulatory Milestones
11.3.3. Other Developmental Activities
11.3.4. Summary of Pivotal Trial
11.3.5. Clinical Development
11.3.5.1. Clinical trials information
11.3.6. Analyst's View
11.4. Alirocumab (PRALUENT): Sanofi/Regeneron Pharmaceuticals
11.4.1. Drug Description
11.4.2. Regulatory Milestones
11.4.3. Other Developmental Activities
11.4.4. Summary of Pivotal Trial
11.4.5. Analyst's View
11.5. Bempedoic acid (NEXLETOL/NILEMDO): Esperion Therapeutics/Daiichi Sankyo/Otsuka
11.5.1. Drug Description
11.5.2. Regulatory Milestones
11.5.3. Other Developmental Activities
11.5.4. Summary of Pivotal Trials
11.5.5. Analyst's View
11.6. Bempedoic acid and ezetimibe (NEXLIZET/NUSTENDI): Esperion Therapeutics/Daiichi Sankyo
11.6.1. Product Description
11.6.2. Regulatory Milestones
11.6.3. Other Developmental Activities
11.6.4. Summary of Pivotal Trials
11.6.5. Analyst's View
11.7. Rivaroxaban (XARELTO): Bayer/Johnson & Johnson
11.7.1. Product Description
11.7.2. Regulatory Milestones
11.7.3. Other Developmental Activities
11.7.4. Summary of Pivotal Trials
11.7.5. Safety and Efficacy
11.7.6. Analyst's View
11.8. Colchicine (Low-Dose Colchicine, LoDoCo): AGEPHA Pharma
11.8.1. Product Description
11.8.2. Regulatory Milestones
11.8.3. Other Developmental Activities
11.8.4. Summary of Pivotal Trials
11.8.5. Analyst's View
11.9. Ticagrelor (BRILINTA): AstraZeneca
11.9.1. Product Description
11.9.2. Regulatory Milestones
11.9.3. Other Developmental Activities
11.9.4. Summary of Pivotal Trials
11.9.5. Analyst's View
11.10. Icosapent ethyl (VASCEPA/VAZKEPA): Amarin Pharmaceuticals
11.10.1. Product Description
11.10.2. Regulatory Milestones
11.10.3. Other Developmental Activities
11.10.4. Summary of Pivotal Trials
11.10.5. Analyst's View
11.11. Semaglutide oral (RYBELSUS): Novo nordisk
11.11.1. Product Description
11.11.2. Regulatory Milestones
11.11.3. Summary of Pivotal Trials
11.11.4. Analyst's View
12. Emerging Therapies
12.1. Key Cross Competition
12.2. Olpasiran (AMG 890): Amgen/Arrowhead Pharmaceuticals
12.2.1. Drug Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.3.1. Clinical Trial Information
12.2.4. Safety and Efficacy
12.2.5. Analyst's View
12.3. Obicetrapib (TA-8995): NewAmsterdam Pharma and Menarini Group
12.3.1. Drug Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.3.1. Clinical Trial Information
12.3.4. Safety and Efficacy
12.3.5. Analyst's View
12.4. Apabetalone (RVX000222): Resverlogix
12.4.1. Drug Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.3.1. Clinical Trial Information
12.4.4. Safety and Efficacy
12.4.5. Analyst's View
12.5. Pelacarsen (TQJ230): Ionis Pharmaceuticals/Novartis
12.5.1. Drug Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.5.3.1. Clinical Trial Information
12.5.4. Safety and Efficacy
12.5.5. Analyst's View
12.6. Lerodalcibep (LIB-003): LIB Therapeutics
12.6.1. Drug Description
12.6.2. Other Developmental Activities
12.6.3. Clinical Development
12.6.3.1. Clinical Trial Information
12.6.4. Safety and Efficacy
12.6.5. Analyst's View
12.7. Laroprovstat (AZD0780): AstraZeneca
12.7.1. Drug Description
12.7.2. Other Developmental Activities
12.7.3. Clinical Development
12.7.3.1. Clinical Trial Information
12.7.4. Safety and Efficacy
12.7.5. Analyst's View
12.8. Enlicitide Decanoate (MK-0616): Merck
12.8.1. Drug Description
12.8.2. Other Developmental Activities
12.8.3. Clinical Development
12.8.3.1. Clinical Trial Information
12.8.4. Safety and Efficacy
12.8.5. Analyst's View
12.9. Maridebart Cafraglutide (MariTide/formerly AMG 133): Amgen
12.9.1. Drug Description
12.9.2. Other Developmental Activities
12.9.3. Clinical Development
12.9.3.1. Clinical Trial Information
12.9.4. Analyst's View
12.10. Orforglipron (LY3502970): Eli Lilly
12.10.1. Drug Description
12.10.2. Other Developmental Activities
12.10.3. Clinical Development
12.10.3.1. Clinical Trial Information
12.10.4. Analyst's View
12.11. Muvalaplin (LY3473329): Eli Lilly
12.11.1. Drug Description
12.11.2. Other Developmental Activities
12.11.3. Clinical Development
12.11.3.1. Clinical Trial Information
12.11.4. Safety and Efficacy
12.11.5. Analyst's View
12.12. Retatrutide (LY3437943): Eli Lilly
12.12.1. Drug Description
12.12.2. Clinical Development
12.12.2.1. Clinical Trial Information
12.12.3. Safety and Efficacy
12.12.4. Analyst's View
12.13. Lepodisiran (LY3819469): Eli Lilly
12.13.1. Drug Description
12.13.2. Other Developmental Activities
12.13.3. Clinical Development
12.13.3.1. Clinical Trial Information
12.13.4. Safety and Efficacy
12.13.5. Analyst's View
12.14. Olezarsen: Ionis Pharmaceuticals
12.14.1. Drug Description
12.14.2. Other Developmental Activities
12.14.3. Clinical Development
12.14.3.1. Clinical Trials Information
12.14.4. Safety and Efficacy
12.14.5. Analyst's View
12.15. Milvexian (BMS-986177; JNJ-70033093): Janssen Research & Development/Bristol-Myers Squibb
12.15.1. Drug Description
12.15.2. Other Developmental Activities
12.15.3. Clinical Development
12.15.3.1. Clinical Trials Information
12.15.4. Analyst's View
12.16. Ziltivekimab (COR 001): Novo Nordisk
12.16.1. Drug Description
12.16.2. Other Developmental Activity
12.16.3. Clinical Development
12.16.3.1. Clinical Trials Information
12.16.4. Safety and Efficacy
12.16.5. Analyst's View
12.17. Dalcetrapib: DalCor Pharmaceuticals
12.17.1. Drug Description
12.17.2. Other Developmental Activities
12.17.3. Clinical Development
12.17.3.1. Clinical Trial Information
12.17.4. Safety and Efficacy
12.17.5. Analyst's View
12.18. Asundexian (BAY2433334): Bayer
12.18.1. Drug Description
12.18.2. Other Developmental Activities
12.18.3. Clinical Development
12.18.3.1. Clinical Trial Information
12.18.4. Analyst's View
12.19. Zodasiran: Arrowhead Pharmaceuticals
12.19.1. Drug Description
12.19.2. Other Developmental Activities
12.19.3. Clinical Development
12.19.3.1. Clinical Trial Information
12.19.4. Safety and Efficacy
12.19.5. Analyst's View
12.20. Zilebesiran: Alnylam Pharmaceuticals/Roche
12.20.1. Drug Description
12.20.2. Other Developmental Activities
12.20.3. Clinical Development
12.20.3.1. Clinical Trial Information
12.20.4. Analyst's View
12.21. Vicagrel: Jiangsu Vcare Pharmaceutical Technology
12.21.1. Drug Description
12.21.2. Other Developmental Activities
12.21.3. Clinical Development
12.21.3.1. Clinical Trial Information
12.21.4. Analyst's View
13. ASCVD: 7MM Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Key Market Forecast Assumptions
13.3.1. Cost Assumptions
13.4. Conjoint Analysis
13.5. Total Market Size of ASCVD in the 7MM
13.6. Total Market Size of ASCVD by Therapies in the 7MM
13.7. The United States
13.7.1. Total Market Size of ASCVD
13.7.2. Market Size of ASCVD by Therapies in the United States
13.8. EU4 and the UK
13.8.1. Total Market Size of ASCVD
13.8.2. Market Size of ASCVD by Therapies in EU4 and the UK
13.9. Japan
13.9.1. Total Market Size of ASCVD
13.9.2. Market Size of ASCVD by Therapies in Japan
14. Unmet Needs of ASCVD
15. SWOT Analysis of ASCVD
16. KOL Views of ASCVD
17. Market Access and Reimbursement of ASCVD
17.1. The United States
17.2. EU4 and the UK
17.2.1. Germany
17.2.2. France
17.2.3. Italy
17.2.4. Spain
17.2.5. United Kingdom
17.3. Japan
18. Appendix
18.1. Bibliography
18.2. Report Methodology
19. Analyst's Capabilities
20. Disclaimer
21. About the Publisher
List of Tables [96]
List of Figures [41]
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/3gps6z
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.